IL-23 therapies are among the most efficacious and safest treatment options for patients with skin psoriasis. The enthusiasm for IL-23 agents for PsA is perhaps more tempered; while efficacy has been demonstrated for peripheral joint disease, there is concern that these agents are not effective in patients with axial disease.
All News
Article
Article
Dr. Jack Cush reviews the FDA approvals and news reports from this past week on RheumNow.com. This week we discuss playing the numbers in rheumatology, playing the long game with stem cell transplants, and a=the Positive spin on seronegative RA.
Article
Sun Pharmaceuticals announced Friday that the FDA has approved its IL-23 inhibitor, tildrakizumab (Ilumya) for use in patients with active psoriatic arthritis.
Article
On this week's podcast, Dr. Jack Cush reviews the news: Steroids are easy to start and hard to stop; hold the MTX but not the biologic or JAK, weighing in on avacopan, and age-old messages for old-age patients.
Antoni Chan MD (Prof)
Tweet
DESIR analysis: the 2025 ASAS SPARTAN criteria classified 44% of 663 patients with early axSpA vs 63% with ASAS 2009. Key finding: sensitivity was lower with the new criteria, mainly in the clinical arm (30.1% to 0.8%), affecting mostly HLA B27 positive patients. @rheumnow #ACR26
Antoni Chan MD (Prof)
Tweet
IL17Ai vs IL23i in PsA, US registry, 385 vs 233 patients: class persistence at 12 months 56.2% vs 57.4% (HR 1.06), drug persistence 48.9% vs 54.1% (HR 1.19). Key finding: persistence did not differ significantly between the two classes. @rheumnow #ACR26 Abstract#2288
David Liew
Tweet
Maybe a slightly gentler incline than bimekizumab & maybe a bit closer to guselkumab, but the new oral IL-23i icotrokinra works in PsA.
It's great to have a potential oral PsA option that is very safe but also has the required modern standard for skin
ABSTLB12 #ACR26 @RheumNow https://t.co/Duofo3ZzZ7
Antoni Chan MD (Prof)
Tweet
Dual targeted therapy in 76 patients with refractory SpA or PsA (Spain), most often TNFi plus IL12/23i. Key finding: 55.6% reached remission during follow up, and adverse events accounted for a third of discontinuations. @rheumnow #ACR26 Abstract#1322
Adela Castro
Tweet
Double targeted therapy in refractory SpA/PsA
Spanish multicentre cohort of 76 refractory SpA/PsA patients on double targeted therapy (DTT), median follow-up 15 months.
-Most common: TNFi + IL-12/23i (30%), then TNFi + IL-17i (17%)
-Mean ASDAS fell from 3.7 to about 2.0 by 6
ACR 2026 – Biotech and Mid-Size Companies Bet on Novel Mechanisms
ACR Convergence 2026 is crowded with first-in-class mechanisms: an oral IL-23 receptor peptide, FcRn blockade, a JAK head-to-head and a wave of cell depletion therapies.
https://t.co/hhUX2ZXJlp https://t.co/rvpzdh56H7
Proposal for clinical remission (CR) and low disease activity (LDA) from VALOR data (brep vs plbo in dermato)
LDA: PtGA-VAS < 4, PhGA-VAS < 4, and OCS dose ≤ 5 mg/d
CR propposal: PtGA-VAS ≤ 1, PhGA-VAS ≤ 1, and OCS ≤ 2.5 mg/d prednisone-equivalent.
Sounds reasonable? https://t.co/jZAJ1IjSTO
Audrey Gibson
Tweet
Mehta et al. (Toronto PsA GLP-1 cohort): lower cDAPSA, DAPSA and pain persisted after adjustment for BMI change, but no significant association with CRP or swollen/tender joint counts. Intriguing, not proof of direct immunomodulation. @rheumnow #ACR2026 Abstract#0373 https://t.co/MUUnk9JJwW
Adela Castro
Tweet
Is sacroiliitis in IBD the same as in primary axSpA?
In a Czech study, 121 patients with suspected enteropathic SpA (eSpA)
out of which 38 had MRI-positive sacroiliitis were compared with 38 axSpA controls matched for age and disease duration. Two blinded readers scored the
FDA Approves Tildrakizumab for Psoriatic Arthritis
Sun Pharmaceuticals announced Friday that the FDA has approved its IL-23 inhibitor, tildrakizumab (Ilumya) for use in patients with active psoriatic arthritis.
https://t.co/9vJoJ35iso https://t.co/KeA3Xh8QG9
FDA Approves Tildrakizumab for Psoriatic Arthritis
Sun Pharmaceuticals announced Friday that the FDA has approved its IL-23 inhibitor, tildrakizumab (Ilumya) for use in patients with active psoriatic arthritis.
https://t.co/9vJoJ35iso https://t.co/4ePITTmPl8
AxSpA SIG : Baraliakos - inflammation drives fatty lesions producing damage and osteoblastic activity
@RheumNow @APLAR2026 https://t.co/GDFSwt2IOm
Mease : future therapy - Be-Bold H2H Bime vs Rizi, Sonelokimab, Izokibep, Deucra, Zaso, Ico, TL1Ainhib
@RheumNow #APLAR2026 https://t.co/Rv5hwnQnDl
Italian retrospective study of 562 plaque psoriasis Rx w/ biologics - 34% were obese. Primary Rx failure signif. more w/ obesity (17% vs 6%; HR 2.75). A 5 kg/m2 BMI incr assoc w/ 37% higher risk. Lower risk of failure w/ IL-17i (HR 0.49) & IL-23i (HR 0.47). Obesity not assoc w/ https://t.co/fUik6pBcnq
The FDA is reviewing Sun Pharma’s tildrakizumab (Ilumya), an IL-23 inhibitor, for use in active psoriatic arthritis, with an October 29, 2026 action (PDUFA) date. Decisons to be based on PsA INSPIRE-1 and INSPIRE-2 Phase 3 Studies https://t.co/iDWhub0k91 https://t.co/j8wQLxNCdA
POETYK PsA-1 - Efficacy and Safety of Deucravacitinib in Psoriatic Arthritis
van der Heijde et al have published the results of the phase 3 POETYK PsA-1 trial demonstrating that deucravacitinib was superior to placebo in clinical responses, patient-reported outcomes, and https://t.co/ovASDqLeWK
